Eton Pharmaceuticals Quarterly Income Statement
NASDAQ: ETONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Eton Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Eton Pharmaceuticals generated $37.6 million in revenue, up 98.6% from the same quarter a year earlier. Net income was $11.6 million, for a net margin of 30.8% versus a median of -8.6% in the prior 5 quarters. Gross margin was 67.6% (up from 63.0%) and operating margin 34.0%.
Diluted earnings per share came in at $0.35.
Summary generated from market data by MetaCap's automated system. Methodology
Eton Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 37.59M | 24.27M | 21.28M | 22.46M | 18.93M | 17.28M | 11.65M | 10.32M | 9.07M | 7.97M | 7.31M | 7.03M |
| Revenue growth (YoY) | +98.59% | +40.41% | +82.72% | +117.54% | +108.60% | +116.95% | +59.26% | +46.90% | -24.36% | +50.19% | -13.94% | +118.33% |
| Cost of Revenue | 12.18M | 9.53M | 8.18M | 14.60M | 7.00M | 7.42M | 5.17M | 4.02M | 3.45M | 2.96M | 3.68M | 2.63M |
| Gross Profit | 25.41M | 14.73M | 13.10M | 7.86M | 11.92M | 9.86M | 6.48M | 6.30M | 5.63M | 5.01M | 3.63M | 4.40M |
| Operating Expenses | 12.62M | 12.32M | 10.64M | 9.22M | 13.40M | 10.33M | 5.85M | 5.79M | 8.56M | 5.81M | 5.62M | 4.95M |
| Research & Development | 993.00K | 1.88M | 1.78M | 1.11M | 3.71M | 1.16M | -871.00K | 505.00K | 2.97M | 651.00K | 1.05M | 615.00K |
| Operating Income | 12.79M | 2.41M | 2.46M | -1.36M | -1.48M | -470.00K | 629.00K | 509.00K | -2.94M | -800.00K | -1.99M | -548.00K |
| Interest Expense | 1.01M | 1.14M | — | 1.21M | 1.20M | 1.16M | 1.51M | 211.00K | 222.00K | 238.00K | 255.00K | 267.00K |
| Other Income (Expense) | — | — | — | — | — | — | -1.14M | -8.00K | -52.00K | -11.00K | -16.00K | -31.00K |
| Pretax Income | 11.72M | 1.57M | 1.41M | -1.96M | -2.52M | -1.50M | -511.00K | 501.00K | -2.99M | -811.00K | -2.01M | -579.00K |
| Income Tax | 140.00K | 20.00K | -69.00K | -28.00K | 66.00K | 74.00K | 87.00K | -126.00K | 54.00K | 0 | 247.00K | 0 |
| Net Income | 11.58M | 1.55M | 1.48M | -1.93M | -2.58M | -1.57M | -598.00K | 627.00K | -3.04M | -811.00K | -2.26M | -579.00K |
| Net Income growth (YoY) | — | — | — | -407.34% | — | — | — | — | -166.70% | — | -347.37% | — |
| EPS (Basic) | 0.42 | 0.06 | 0.06 | -0.07 | -0.10 | -0.06 | -0.02 | 0.02 | -0.12 | -0.03 | -0.10 | -0.02 |
| EPS (Diluted) | 0.35 | 0.05 | — | -0.07 | -0.10 | -0.06 | — | 0.02 | -0.12 | -0.03 | — | -0.02 |
| Shares Outstanding (Basic) | 27.64M | 27.29M | — | 26.89M | 26.89M | 26.89M | — | 25.90M | 25.78M | 25.76M | — | 25.72K |
| Shares Outstanding (Diluted) | 32.79M | 31.55M | — | 26.89M | 26.89M | 26.89M | — | 26.55M | 25.78K | 25.76K | — | 25.72K |
| EBITDA | 14.18M | 3.54M | 3.48M | -354.00K | -470.00K | 543.00K | 984.00K | 787.00K | -2.66M | -566.00K | -1.67M | -357.00K |
| Gross Margin | 67.61% | 60.72% | 61.56% | 34.97% | 63.00% | 57.06% | 55.60% | 61.04% | 62.00% | 62.85% | 49.64% | 62.65% |
| Operating Margin | 34.04% | 9.95% | 11.58% | -6.07% | -7.79% | -2.72% | 5.40% | 4.93% | -32.35% | -10.04% | -27.25% | -7.80% |
| Net Margin | 30.80% | 6.40% | 6.97% | -8.58% | -13.66% | -9.10% | -5.13% | 6.07% | -33.51% | -10.18% | -30.85% | -8.24% |
This table shows 12 quarterly periods of Eton Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ETON's reporting calendar. What is a income statement?